Literature DB >> 10972517

Regulation of follicle development and novel approaches to ovarian stimulation for IVF.

N Smacklon1, B C Fauser.   

Abstract

Current ovarian stimulation regimens for IVF are complex and not without risk. Increasing our knowledge of the physiology of follicle development and dominant follicle selection may enable the design of less complex, safer and cheaper ovarian stimulation regimens for IVF. Decremental serum FSH concentrations during the follicular phase of the menstrual cycle are required for single dominant follicle selection. Only the most mature follicle will continue its development due to increased sensitivity for stimulation by FSH. FSH stimulation becomes insufficient for less mature follicles and remaining cohort follicles will therefore go into atresia. The number of days during which FSH is above the threshold for stimulation of follicle development is limited, resulting in a narrow FSH window. More medium sized and large pre-ovulatory follicles and increased oestradiol output can be induced by the administration of small doses of exogenous FSH during the mid- to late follicular phase, preventing the physiological decrease in FSH stimulation. Intervention with decremental serum FSH concentrations in combination with gonadotrophin-releasing hormone (GnRH) antagonists to prevent a premature rise in serum LH may induce ongoing growth of multiple follicles sufficient for IVF. The benefits and risks of these minimal hyperstimulation protocols require further evaluation.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10972517     DOI: 10.1093/humupd/6.4.307

Source DB:  PubMed          Journal:  Hum Reprod Update        ISSN: 1355-4786            Impact factor:   15.610


  8 in total

1.  Association of inhibin B serum levels with parameters of follicular response in a randomized controlled trial comparing gnRH agonist versus antagonist protocols for ovarian hyperstimulation.

Authors:  Barbara Sonntag; Ludwig Kiesel; Eberhard Nieschlag; Hermann M Behre
Journal:  J Assist Reprod Genet       Date:  2004-07       Impact factor: 3.412

Review 2.  Novel Concepts for Inducing Final Oocyte Maturation in In Vitro Fertilization Treatment.

Authors:  Ali Abbara; Sophie A Clarke; Waljit S Dhillo
Journal:  Endocr Rev       Date:  2018-10-01       Impact factor: 19.871

3.  Role of transient hyperprolactinemia in the late follicular phase of the gonadotropin-stimulated cycle.

Authors:  Shuji Takiguchi; Yasuhiko Nakamura; Yoshiaki Yamagata; Hisako Takayama; Ayako Harada; Norihiro Sugino; Hiroshi Kato
Journal:  Reprod Med Biol       Date:  2002-12-11

Review 4.  Progress in understanding human ovarian folliculogenesis and its implications in assisted reproduction.

Authors:  Dong Zi Yang; Wan Yang; Yu Li; Zuanyu He
Journal:  J Assist Reprod Genet       Date:  2013-02       Impact factor: 3.412

Review 5.  Contemporary pharmacological manipulation in assisted reproduction.

Authors:  Judith A F Huirne; Cornelis B Lambalk; Andre C D van Loenen; Roel Schats; Peter G A Hompes; Bart C J M Fauser; Nick S Macklon
Journal:  Drugs       Date:  2004       Impact factor: 9.546

Review 6.  Ovarian follicular development during the use of oral contraception: a review.

Authors:  Angela R Baerwald; Roger A Pierson
Journal:  J Obstet Gynaecol Can       Date:  2004-01

7.  Non-invasive prediction of implantation window in controlled hyperstimulation cycles: Can the time from the menstrual day at embryo transfer to expected menstrual cycle give a clue?

Authors:  İlhan Şanverdi; Enis Özkaya; Tayfun Kutlu; Taylan Şenol; Munip Akalın; Eda Sayar Akalın; Yavuz Şahin; Ateş Karateke
Journal:  Turk J Obstet Gynecol       Date:  2016-09-15

8.  FSH Requirements for Follicle Growth During Controlled Ovarian Stimulation.

Authors:  Ali Abbara; Aaran Patel; Tia Hunjan; Sophie A Clarke; Germaine Chia; Pei Chia Eng; Maria Phylactou; Alexander N Comninos; Stuart Lavery; Geoffrey H Trew; Rehan Salim; Raj S Rai; Tom W Kelsey; Waljit S Dhillo
Journal:  Front Endocrinol (Lausanne)       Date:  2019-08-27       Impact factor: 5.555

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.